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ABSTRACT
Objective: Metformin hydrochloride is a biguanide antihyperglycemic agent which is a generally recommended first-line drug for the treatment of 
diabetes mellitus (Type II). The purpose of this investigation is to prepare sustained release matrix granules of metformin hydrochloride which are 
coated to extend the drug release over a longer time period.
Methods: Metformin hydrochloride granules were prepared by mixing all the dry powders in a V-cone blender and wetting the powder mix with 
aqueous solution of hydroxypropyl methyl cellulose K100. The prepared granules (MG1-MG5) were investigated for drug release. The batch of 
granules which exhibited extended release for up to 4 h was coated in a standard coating pan with blends of Eudragit RS and RL to further enhance 
release period. These were marked as coated metformin granules (CMG3) and CMG4 which were later filled into empty capsules. The granules were 
characterized for micromeritic properties, percentage yield, particle size distribution, percentage of drug content, and in vitro release of the drug.
Results: All the formulations showed percentage yield in the range of 77.66–82.86% and drug content in the range of 78.23–96.62%. CMG3 showed 
drug release of 97.02% for 12 h. Fourier-transform infrared spectroscopy and differential scanning calorimetry studies indicated that no possible 
interaction existed between the drug and the polymers used. Scanning electron microscopy images revealed that the granules were spherical in shape 
with smooth surface and completely covered with a coating of polymer. Kinetic analysis of drug release confirmed that drug release followed zero-
order kinetics where it is independent of the concentration.
Conclusion: From the results, it was analyzed that design of coated granules employing the polymers used in the present work can produce a 
sustained release of the drug over a period of 12 h.
Keywords: Metformin, Sustained release, V-cone blender, Eudragit, Standard coating pan.
INTRODUCTION
The design of sustained dosage forms is to slowly release the drug over 
an extended time period. They possess a major advantage of improved 
patient compliance as the dosing frequency is once or twice daily [1]. 
In case of dosage forms for extended release, multiple unit forms are 
mostly preferred over single unit dosage forms as they contain a minute 
amount of the drug and thus have a lower risk of dose dumping [2].
Metformin hydrochloride (Fig. 1) is a potent antidiabetic drug with 
a major drawback of shorter elimination half-life (6.2 h). It acts in 
the presence of insulin to enhance glucose use and decrease the 
production of glucose by counteracting insulin resistance. The effect 
of metformin includes enhanced glucose uptake and reduced hepatic 
gluconeogenesis. Drugs with shorter biological half-life are suitable 
candidates for formulation in sustained release dosage forms [3,4].
The aim of the current investigation is to formulate coated granules 
of metformin hydrochloride. To overcome the drawback of shorter 
elimination half-life and fluctuations in plasma level concentration of 
the drug, an attempt was made to sustain the release of the drug by 
formulating it as coated granules using retardant polymers.
METHODS
Materials
Metformin hydrochloride, Eudragit RS and RL 100, and hydroxypropyl 
methylcellulose (HPMC) K 100M were obtained from Yarrow Chem 
Products, ethyl cellulose from Otto, and dicalcium phosphate and 
propylene glycol from Finar Chemicals.
Preparation of sustained release matrix granules
Different batches of granules (MG1, MG2, MG3, MG4, and MG5) were 
prepared according to the composition mentioned in Table 1. Accurately 
weighed quantities of each component were mixed in a V-cone blender. 
The powder mix was wetted with an aqueous solution of HPMC K 
100 (7.5%, w/w). The granules obtained after passing through a sieve 
(10 mesh size) were then dried adequately at 60°C for 30–45 min. The dried 
granules were sifted manually through 10 mesh screen. The matrix granules 
in particle size range of 10–22 mesh had been selected. These batches of 
granules were put under physical characterization and drug release study.
Coating of sustained release matrix granules
The granules which exhibited extended release up to 4 h (MG3 and 
MG4) needed further modification to enhance release period. Matrix 
granules (10–22 mesh size) were coated stepwise in a standard pan 
coater. Metformin matrix granules were coated with blends of Eudragit® 
RS and RL along with plasticizer and propylene glycol (20% w/w). All 
dispersions were plasticized overnight. Eudragit® RS and RL blend 
ratios were investigated at 85:15 (w/w), and this caused 10% weight 
gain in granules. After coating, these granules were marked as batch 
coated metformin granules (CMG3) and CMG4. Coated CMG3 batch had 
sustained the drug release for a longer period of 12 h. These coated 
batches were later subjected to physicochemical characterization tests 
and in vitro release study [5,6].
Compatibility studies
Fourier transform infrared (FTIR) analysis
The FTIR spectra of prepared granules were scanned over a frequency 
range of 4000–400/cm. A little quantity of sample was placed on 
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diamond attenuated total reflection and analyzed for the presence of 
characteristic peaks.
Differential scanning calorimetry (DSC)
The DSC analysis of pure drug and coated and uncoated granules 
was carried out to evaluate any possible drug-polymer interaction. 
The analysis was performed at a rate of 10°C min−1 from 20°C–30°C 
temperature range under nitrogen flow of 25 ml/min [7].
Surface morphology
The morphology of coated granules was investigated by scanning 
electron microscopy (SEM) at an accelerating voltage of 1.0 kV.
Characterization of granules
Determination of micromeritic properties
The granules were characterized for their bulk density, tapped density, 
compressibility index, Hausner’s ratio, and angle of repose [8].
Percentage yield (% yield)
It is the weight of final product after drying to the initial weight of drug 
and polymer used for preparation of granules. The percentage yield was 
calculated using the following formula:
Percentage yield
Weight of the granules
Total weight o
   





   
  
×100
Estimation of drug content
A weighed quantity of granules (equivalent to 100 mg of a drug) was 
crushed into powder and added to 100 ml of pH 6.8 phosphate buffer. 
The resulting mixture was stirred for 2 h and kept overnight. Then, the 
solution was filtered through the Whatman’s filter paper, and 1 ml of 
this solution was diluted using pH 6.8 phosphate buffer and analyzed 








iotical drug content  
×100
Determination of particle size distribution by sieve analysis
A mechanical sieve shaker was employed for partitioning the granules 
into different size meshes. A stack of 5 numbers of standard stainless steel 
sieves (Ajantha Sieves, Chennai, India) were placed in a sequence of their 
increasing pore size (bottom to top) over a sieve shaker. Accurately 10 g of 
granules from different formulated batches were loaded on the topmost 
sieve. Then, the sieve shaker was operated for a 10 min period. Granules 
retained over each sieve were collected and weighed accurately [9].
In vitro drug release studies
The in vitro drug release studies were performed using USP dissolution 
apparatus. The dissolution medium consisted of pH 6.8 phosphate buffer 
(900 ml) and was maintained at 37±0.5°C. At specified time intervals, 
5 ml aliquot was withdrawn and immediately replaced with the same 
volume of fresh buffer maintained at the same temperature. The drug 
release was determined using ultraviolet-visible spectrophotometer at 
235 nm. The dissolution studies were conducted in triplicate, and the 
mean percentage cumulative drug release was plotted against time of 
drug release [10].
Kinetics of drug release
Mathematical modeling is a significant approach in the optimization 
of a formulation because its development utilizes comprehension of 
all the parameters affecting drug release kinetics. The various model-
dependent approaches include zero-order, first-order, Higuchi, Hixson–
Crowell, and Korsmeyer–Peppas.
Qt=Q0+k0t (1)
log Q= log Q0– kt/2.303 (2)
Qt=kHC*t1/2 (3)
Qo1/3-Q1/3=kt (4)
Mt/M∞=k tn  (5)Fig. 1: Structure of metformin hydrochloride
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Where
Qt is the amount of drug released at time t;
Q0 is the initial amount of the drug in the formulation;
k0, k1, kH, and kHC are release rate constants for zero-order, first-order, 
Higuchi model, and Hixson–Crowell rate equations.
Mt is the amount of drug released at time t,
M∞ is the amount of drug released at time ∞;
k is the kinetic constant,
n is the diffusion coefficient.
The release data of various formulations were fitted in various models 
to ascertain the mechanism of drug release [11,12].
RESULTS AND DISCUSSION
Preparation of sustained release matrix granules
Different batches of granules (MG1, MG2, MG3, MG4, and MG5) were 
prepared according to the composition mentioned in Table 1.
Compatibility studies
FTIR analysis
The IR spectrum of metformin hydrochloride showed the existence of 
characteristic peaks corresponding to the functional groups present in 
the drug structure. IR spectra of metformin hydrochloride peaks were 
found at 1062.3 cm-1 (C-N stretching), 3367.0/cm (NH stretching), 
1623.3/cm (C=O stretching), and 2151.5/cm (azide group). The 
presence of any interaction between drug and polymers used often 
leads to significant changes in IR spectra of the drug-polymer mixture. 
From the IR spectra of drug-polymer mixture, it was found that there 
occurred no major shift in the frequencies of the characteristics 
functional groups of the drug. The absence of significant shifting in 
intensity of peaks and bandwidth of the excipients showed that no 
incompatibilities occurred between the drug and polymers used.
DSC
DSC thermogram of metformin hydrochloride (Fig. 2) showed a sharp 
endothermic peak at 231.03°C corresponding to its melting point. The 
obtained value matched with the value given in literature. In the DSC 
curve of metformin hydrochloride granules, the original peaks were 
retained and no additional peaks were obtained. This indicated that 
metformin hydrochloride with other polymers has better compatibility.
Characterization of granules
Determination of micromeritic properties
Flow properties such as angle of repose, bulk density, tapped density, 
Carr’s index, and Hausner’s ratio of the granules mentioned in Table 2. 
The bulk density of granules was found to be between 0.39 and 
0.425 g/cm3, tapped density was 0.447 and 0.43 g/cm3, Carr’s index 
was found to be between 4.54 and 9.30%, Hausner’s ratio was 1.04 and 
1.10, and angle of repose was found to be 23.74 and 20.30°. The flow 
properties of different batches of granules were excellent as the angle 
of repose values were found to be <25, compressibility index <15%, and 
Hausner’s ratio <1.25 in case of all the batches.
Percentage Yield (% yield)
Percentage yield of different batches was in the range of 77.66–82.86%. 
All the batches of granules showed more than 75% yield.
Estimation of drug content
The drug content for all the formulations was found to be in the range of 
78.23–96.62% as shown in Table 3. These values indicated uniformity 
of drug content in each batch of granules.
Determination of particle size distribution by sieve analysis
Particle size distributions of various formulated batches of 
microspheres (Table 4) were found to be within a lean dimension 
(i.e.,605–1205 µm). A major fraction of the granules (75–85.43%) in 
Table 1: Formulation composition for metformin‑loaded granules
Formulation code Drug (mg) Ethyl cellulose (mg) Di‑ calcium phosphate (mg) HPMC K100M (% w/w) Total
MG1 500 0 100 7.5 600
MG2 500 10 90 7.5 600
MG3 500 20 80 7.5 600
MG4 500 30 70 7.5 600
MG5 500 40 60 7.5 600
HPMC: Hydroxypropyl methylcellulose
Table 2: Flow properties of metformin granules
Formulation codes Angle of repose(θ°) Bulk density (g/cm3) Tapped density (g/cm3) Hausner’s ratio Carr’s index (%)
MG1 21.76 0.397 0.428 1.07 7.24
MG2 26.54 0.416 0.432 1.03 3.70
MG3 23.74 0.425 0.447 1.05 4.54
MG4 20.30 0.390 0.430 1.10 9.30
MG5 25.19 0.421 0.443 1.05 4.96
Fig. 3:  In vitro release of uncoated drug release
Table 3: Percentage yield and drug content
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case of all the formulated batches were within a range of −10–+22 
(i.e., 1205 µm) mesh size.
In vitro drug release studies
The cumulative in vitro release studies of different formulations of 
metformin (MG1-MG5) were performed in pH 6.8 phosphate buffer 
for 4 h. The samples were spectrophotometrically analyzed at 235 nm 
and the values mentioned in Table 5. The results (Fig. 3) showed that in 
case of formulations MG3 and MG4, the concentration of polymers used 
showed retardation in the drug release. To further sustain the release of 
drug over a longer period of time, these batches of granules were coated 
further with retardant polymers.
Surface morphology
The SEM photographs of metformin hydrochloride (Fig. 4) indicated 
that the drug was crystalline in nature. SEM photographs of optimized 
formulation consisting of uncoated metformin granules indicated that 
these were discrete and free flowing. These photograph studies of the 
coated granules indicated that granules were spherical with smooth 
surface and completely covered with the polymer coat.
In vitro drug release studies of coated granules
The cumulative in vitro release studies of CMG3 and CMG4 
were performed in pH 6.8 phosphate buffer, and samples were 
Table 4: Size distribution analysis of metformin granules
Granules Batch Percentage retained
−10/+22 (1205 µm) −22/+30 (605 µm) −30/+44 (427.5 µm) −44/+60 (302.5 µm)
MG1 1 7.210 0.920 0.490 0.250
2 7.450 0.890 0.450 0.280
3 7.112 0.790 0.475 0.190
Mean±SD 7.257±0.1419 0.866±0.055 0.471±0.016 0.593±0.037
MG2 1 6.942 0.985 0.560 0.420
2 5.071 1.120 0.520 0.482
3 6.253 0.965 0.598 0.412
Mean±SD 6.088±0.772 1.023±0.068 0.520±0.031 0.438±0.031
MG3 1 7.880 0.880 0.450 0.210
2 7.250 0.765 0.470 0.195
3 7.430 0.825 0.415 0.170
Mean±SD 7.52±0.264 0.823±0.046 0.445±0.022 0.191±0.016
MG4 1 7.980 0.775 0.425 0.190
2 7.550 0.595 0.480 0.210
3 7.630 0.695 0.415 0.165
Mean±SD 7.72±0.186 0.688±0.073 0.44±0.028 0.188±0.018
MG5 1 6.980 0.995 0.750 0.395
2 7.210 1.110 0.710 0.310
3 7.450 0.955 0.695 0.295
Mean±SD 7.21±0.191 1.02±0.065 0.718±0.023 0.333±0.044
SD: Standard deviation
Table 5: Cumulative percent drug release data of uncoated granules for the selection of formulation for coating
Time (min) % cumulative drug release
MG1 MG2 MG3 MG4 MG5
30 75.46±0.67 73.19±1.36 77.18±1.36 40.86±0.32 8.35±0.31
60 79.25±0.25 79.2±1.98 79.54±1.10 69.59±0.54 10.25±0.25
90 80.12±0.39 80.55±0.65 82.64±0.96 71.04±0.62 12.36±0.24
120 82.08±0.45 84.38±0.98 83.75±0.34 76.44±0.12 15.35±0.66
150 84.30±0.65 86.26±0.21 84.6±0.41 76.81±0.98 19.98±0.22
180 84.60±1.98 90.34±0.36 85.42±0.49 80.33±0.62 22.56±0.98
210 89.00±0.39 93.44±0.99 87.43±1.42 81±0.24 25.52±0.65
240 100.89±1.25 96.27±1.96 87.56±1.65 91.05±0.99 28.25±0.19
Mean±SD, n=3. SD: Standard deviation
Fig. 5: Dissolution data for coated granules. Mean±standard 
deviation, n=3
Fig. 4: Scanning electron microscopy images of (a) metformin 
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Table 6: Dissolution data of coated metformin granules














spectrophotometrically analyzed at 235 nm. The values were mentioned 
in Table 6. It was found that CMG3 (Fig. 5) showed a better sustainable 
drug release of 97.02% within 12 h.
Kinetics of drug release
Release data were analyzed as per zero-order, first-order, Higuchi, 
and Korsmeyer–Peppas equation models to assess the probable drug 
release kinetics from the coated granules. The values were shown in 
Table 7.
Analysis of the release data as per different kinetic models (Fig. 6) 
indicated that metformin release from these granules was best fit 
toward zero-order kinetics. Correlation coefficient (r2) values in the 
zero-order models were higher than those in the first order, indicating 
that the drug release was independent of drug concentration. 
Table 7: Data of release kinetics study
Formulation code Zero order First order Higuchi model Hixson–Crowell Korsmeyer’s–Peppas
r2 K0 r2 K1 r2 KH r2 k r2 N
MG1 0.519 0.255 0.928 0.003 0.765 5.168 0.942 0.003 0.882 0.814
MG2 0.541 0.263 0.926 0.008 0.796 5.331 0.785 0.009 0.893 0.819
MG3 0.412 0.219 0.967 0.002 0.688 4.727 0.622 0.005 0.870 0.806
MG4 0.692 0.284 0.847 0.006 0.903 5.424 0.839 0.006 0.935 0.816
MG5 0.981 0.164 0.980 0.002 0.961 2.714 0.830 0.015 0.997 0.673
CMG3 0.968 7.201 0.847 0.249 0.974 27.91 0.936 0.233 0.958 0.558
CMG4 0.986 6.975 0.850 0.181 0.951 26.46 0.928 0.193 0.974 0.705
Correlation coefficient (r2) values in Higuchi model suggests that the 
release of drug was following diffusion type of mechanism which is 
generally seen in case of swellable matrices.
CONCLUSION
From the results, we can conclude that design of coated granules 
employing polymers mentioned above showed a better-sustained 
release of metformin hydrochloride for 12 h.
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